Skip to main content

Table 4 Distribution of 65 Zn 7 days after gavage administration of 65 ZnO or SiO 2 -coated 65 ZnO NPs in rats

From: Bioavailability, distribution and clearance of tracheally-instilled and gavaged uncoated or silica-coated zinc oxide nanoparticles

 

65ZnO

SiO2-coated65ZnO

 

Mean ± SE

Mean ± SE

Lungs

0.04 ± 0.01

0.06 ± 0.01

Blood

0.23 ± 0.03

0.22 ± 0.04

Lymph nodes

0.02 ± 0.003

0.06 ± 0.01 #

Bone marrow

0.49 ± 0.06

0.47 ± 0.09

Bone

1.62 ± 0.26

2.20 ± 0.45

Skin

1.13 ± 0.14

1.77 ± 0.29

Brain

0.03 ± 0.002

0.04 ± 0.005

Skeletal muscle

2.45 ± 0.36*

0.20 ± 0.03

Testes

0.14 ± 0.01

0.19 ± 0.03

Kidneys

0.08 ± 0.01

0.09 ± 0.01

Spleen

0.02 ± 0.004

0.02 ± 0.004

Heart

0.03 ± 0.003

0.02 ± 0.004

Liver

0.58 ± 0.07

0.71 ± 0.09

Stomach

0.07 ± 0.01

0.09 ± 0.01

Small intestine

0.25 ± 0.03

0.36 ± 0.05

Large intestine

0.09 ± 0.02

0.11 ± 0.01

Cecum

0.13 ± 0.02

0.12 ± 0.02

Total recovered

100.59 ± 2.56*

83.40 ± 2.42

  1. Data are mean ± SE% gavaged dose, n = 5/group.
  2. Total recovered = sum of 65Zn in analyzed organs, feces and urine.
  3. *P < 0.05, ZnO > SiO2-coated ZnO.
  4. # P <0.05, SiO2-coated ZnO > ZnO.
Back to article page

Particle and Fibre Toxicology

ISSN: 1743-8977

Contact us